Human Stem Cells Institute Becomes a Stockholder in Artgen, Inc.

HSCI Announces 9mo 2016 Consolidated Results under IFRS

Human Stem Cells Institute Licenses Its Innovative Ischemia Drug to ArtGen, Inc. for Development in the United States and Canada

Human Stem Cells Institute (HSCI) announced that HSCI’s GENETICO Medical Center & Testing Lab has received 300 million rubles from the Russian State Industry Development Fund.

PJSC HSCI, announced its unaudited consolidated interim results for the first half of 2016 in accordance with the International Financial Reporting Standards (IFRS).

PJSC HSCI – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, announced its plans to raise capital for growth by holding secondary public offering (SPO) on the Moscow Exchange in autumn 2016.

PJSC HSCI, announced its unaudited unconsolidated results for the first half of 2016 in accordance with the Russian Accounting Standards (RAS):

PJSC HSCI today announced the results of the Annual General Shareholders’ Meeting (AGM) held on June 16, 2016 in Moscow.

The Human Stem Cells Institute, today announced the decision of the Company’s Board of Directors to recommend the following annual dividends for 2015 to the Annual General Shareholder’s Meeting

PJSC HSCI, today announced its audited consolidated results for the full year 2015 in accordance with the International Financial Reporting Standards (IFRS)